•
Jun 30, 2021

Bio-Techne Q4 2021 Earnings Report

Bio-Techne team delivered strong organic growth and profitability.

Key Takeaways

Bio-Techne reported a strong fourth quarter with a 39% increase in organic revenue and an adjusted operating margin of 38.5%. The company's Protein Sciences and Diagnostics and Genomics segments achieved record organic growth. Management sees continued momentum as they penetrate the life science markets.

Fourth quarter organic revenue increased by 39% (47% reported) to $259.0 million.

GAAP EPS was $0.37 versus $1.48 one year ago. Adjusted EPS of $1.87 versus $1.00 one year ago.

Adjusted Operating Margin increased to 38.5% in the fourth quarter of fiscal 2021 compared to 31.1% in the fourth quarter of fiscal 2020.

Protein Sciences and Diagnostics and Genomics achieving record organic growth of 46% and 22%, respectively.

Total Revenue
$259M
Previous year: $176M
+47.3%
EPS
$0.47
Previous year: $0.25
+88.0%
Organic Sales Growth
39%
Previous year: -8%
-587.5%
Gross Profit
$176M
Previous year: $113M
+55.3%
Cash and Equivalents
$199M
Previous year: $147M
+35.8%
Free Cash Flow
$111M
Previous year: $27.4M
+303.8%
Total Assets
$2.26B
Previous year: $2.03B
+11.6%

Bio-Techne

Bio-Techne

Bio-Techne Revenue by Segment

Forward Guidance

Bio-Techne sees continued momentum as they increase their penetration into the life science markets they serve, and their businesses reach and exceed the tipping points in size necessary to accelerate growth.